On the Horizon

Alimentary Health’s (AH) opportunity for significant growth is to establish its probiotic based technology as front line therapy for a number of chronic inflammatory diseases and disorders including Irritable Bowel Syndrome (IBS) and its related conditions which today have significant unmet medical need.

The recent spate of product withdrawals in the US highlights the opportunity for safe efficacious technologies in chronic mild to moderate conditions such as IBS treatment.

AH’s Bif 35624 technology is ideally positioned to capitalise on the current void in the IBS market.